Press Releases
Osivax Announces Last Patient Last Visit in Two Phase 2a Clinical Trials with Broad-Spectrum Influenza Vaccine Candidate OVX836 Lyon, France – December 21, …
Osivax Appoints Vincent Bille as Chief Manufacturing Officer and Announces Manufacturing Progress for OVX836 Dr. Bille will oversee manufacturing scale-up for broad-spectrum …
Osivax Announces Clinical and Preclinical Vaccine Data Presentations at Upcoming Global Influenza Conferences Influenza vaccine candidate OVX836 safety profile and efficacy signals …
Publications
Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: a randomised, double-blind, placebo-controlled, phase 2a trial.
Leroux-Roels I et al.
THE LANCET Infectious Diseases, Jul. 2023. doi: 10.1016/S1473-3099(23)00351-1
Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine.
Leroux-Roels I et al.
Frontiers in Immunology, Apr. 2022. doi: 10.3389/fimmu.2022.852904
Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results.
Withanage K et al.
The Journal of Infectious Diseases, Oct. 2021. doi: 10.1093/infdis/jiab532
OVX836 Heptameric Nucleoprotein Vaccine Generates Lung Tissue-Resident Memory CD8+ T-Cells for Cross-Protection Against Influenza.
Del Campo J et al.
Frontiers in Immunology, Jun. 2021. doi: 10.3389/fimmu.2021.678483
OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes.
Del Campo J et al.
Nature partner journals, Jan. 2019. doi: 10.1038/s41541-019-0098-4.
OVX033, a nucleocapsid-based vaccine candidate provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model
Primard C et al.
Frontiers in Immunology, Jun. 2023. doi: 10.3389/fimmu.2023.1188605
A safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity.
Zhao X et al.
npj Vaccines, 2024 Jun. 9:119. doi: 10.1038/s41541-024-00914-z
Combined prophylactic and therapeutic immune responses against human papillomaviruses induced by a thioredoxin-based L2-E7 nanoparticle vaccine.
Zhao X et al.
PLoS Pathogens, 2020 Sep. 16(9):e1008827. doi: 10.1371/journal.ppat.1008827
Minor capsid protein L2 polytope induces broad protection against oncogenic and mucosal human papillomaviruses.
Pouyanfard S et al.
Journal of Virology, 2018 Feb. 92:e01930-17. doi: 10.1128/JVI.01930-17.
Broadly neutralizing antiviral responses induced by a single-molecule HPV vaccine based on thermostable thioredoxin-L2 multiepitope nanoparticles.
Spagnoli G et al.
Scientific Reports, 2017 Dec. 7: 18000. doi: 10.1038/s41598-017-18177-1.
SnoopLigase peptide-peptide conjugation enables modular vaccine assembly
Andersson AC et al.
Scientific Reports, Mar. 2019. 15;9(1):4625. doi: 10.1038/s41598-019-40985-w.
Combination of RTS,S and Pfs25-IMX313 Induces a Functional Antibody Response Against Malaria Infection and Transmission in Mice.
Brod F et al.
Frontiers in Immunology, Dec. 2018. 4;9:2780. doi: 10.3389/fimmu.2018.02780.
Dual Plug-and-Display Synthetic Assembly Using Orthogonal Reactive Proteins for Twin Antigen Immunization.
Brune KD et al.
Bioconjugate Chemistry, May 2017. 17;28(5):1544-1551. doi: 10.1021/acs.bioconjchem.7b00174.
A HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice.
Tomusange K et al.
Scientif Reports, Jun. 2016. 30;6:29131. doi: 10.1038/srep29131.
Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology.
Li Y et al.
Scientific Reports, Jan. 2016. 8;6:18848. doi: 10.1038/srep18848.
T Cell Responses Induced by Adenoviral Vectored Vaccines Can Be Adjuvanted by Fusion of Antigen to the Oligomerization Domain of C4b-Binding Protein.
Forbes EK et al.
PLoS ONE, Sep. 2012. 7(9):e44943. doi:10.1371/journal.pone.0044943.
Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates.
Spencer AJ et al.
PLoS ONE, Mar. 2012. 7(3): e33555. doi:10.1371/journal.pone.0033555.
Immunocontraception in male feral swine treated with a recombinant gonadotropin-releasing hormone vaccine.
Campbell TA,et al.
Journal of Swine Health and Production, May 2010. 18(3):118-124.
The oligomerization domain of C4-binding protein (C4bp) acts as an adjuvant, and the fusion protein comprised of the 19-kilodalton merozoite surface protein 1 fused with the murine C4bp domain protects mice against malaria.
Ogun SA et al.
Infection and Immunity, Aug. 2008. 76(8):3817-3823. doi:10.1128/IAI.01369-07.
Effective induction of high-titer antibodies by viral vector vaccines.
Draper SJ et al.
Nature Medicine, Aug. 2008.14(8):819-821. doi: 10.1038/nm.1850.
Events
Belfast – Oral Presentation and Posters
Delphine Guyon-Gellin, Chief of Business Development of Osivax, to provide preclinical results obtained with OVX033 as part of a presentation entitled “OVX033, T-cell based vaccine targeting the nucleocapsid provides broad-spectrum protection against SARS-COV-2 VoC in Hamster challenge model”. Two more posters entitled “Results of a phase 2 study with OVX836 suggest effectiveness in preventing Influenza-Like Illness and confirm good safety profile” and “How to drastically improve influenza prevention: the addition of a T-cell component to increase current vaccine efficacy, preclinical and early clinical results” are also presented.
Oxford – Oral Presentation
Delphine Guyon-Gellin, Chief of Business Development of Osivax, to provide latest clinical results obtained with OVX836 as part of a presentation entitled “Results of a phase 2 study with OVX836 suggest effectiveness in preventing Influenza-Like Illness and confirm good safety profile”.
Washington DC – Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical Development Update on OVX836 disruptive T-cell vaccine for broad-protection against multiple influenza strains”.